This study examines people with no cognitive difficulties, mild cognitive impairment or Alzheimer’s disease who have genetics that causes Alzheimer’s disease. The goal is to test the safety and effectiveness of new study drugs, including antibodies targeting the protein amyloid-beta that builds up in the brains of people with Alzheimer’s disease. The study also aims to observe participants over time to monitor their daily function and to find ways to improve diagnosis.
Eligibility- Who can participate?
be between the ages of 18 and 80 years
know they have an Alzheimer’s disease-causing mutation or be unaware of their genetic status and have an autosomal dominant Alzheimer’s disease gene mutation in their family (genetic or autopsy report required)
have no cognitive issues, mild cognitive impairment or mild dementia
Maximum of 17 visits over 4 years or less. The visits will include brain imaging, cognitive testing, neurological and physical exams, and taking biosamples (i.e. blood, urine)
Do you have questions about research studies you saw on this page? Please contact email@example.com
The listing of a study on the Toronto Dementia Network (TDN) is for informational purposes only. The safety, efficacy or scientific validity of the studies listed here have not been evaluated by The Alzheimer Society of Toronto (AST) or the Toronto Dementia Research Alliance (TDRA). The TDRA is an academic coalition among the University of Toronto and four memory clinics across Toronto at Baycrest, the Centre for Addiction and Mental Health, Sunnybrook Health Sciences Centre, and the University Health Network. The information collected will be kept and guarded by TDRA. Choosing to participate in a study is an important personal decision. Before you participate in a study, you should make sure you understand the risks and potential benefits and discuss all options with your health care provider(s).